Trading between perceived risks and benefits related to biosimilar biological treatment in Crohn’s disease; discrete choice experiment among gastroenterologists

Petra Baji, László Gulácsi, Barbara D. Lovász, Petra A. Golovics, Valentin Brodszky, Márta Péntek, Fanni Rencz and Péter L. Lakatos

Corvinus Economics Working Papers (CEWP) from Corvinus University of Budapest

Abstract: Objective: The objective of the study is to explore preferences of gastroenterologists for biosimilar drugs in Crohn’s Disease and reveal trade-offs between the perceived risks and benefits related to biosimilar drugs. Method: Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May, 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator) 2) severity of disease 3) availability of continuous medicine supply 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator 2) willing to consider biosimilar for biological-naïve patients only 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. Results: Men, senior consultants, working in IBD center and treating more patients are more likely to willing to consider biosimilar for biological-naïve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in the case biological-naïve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89% vs 11% for new patients, and 44% vs 56% for patients already treated with biological. Conclusions: Gastroenterologists were willing to trade between perceived risks and benefits of biosimilars. The continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.

Keywords: risk perception; biologicals; biosimilars; Crohn’s Disease; Discrete Choice Experiment; Preferences (search for similar items in EconPapers)
JEL-codes: D12 I12 I18 (search for similar items in EconPapers)
Date: 2015-10-01
New Economics Papers: this item is included in nep-dcm and nep-hea
References: Add references at CitEc
Citations:

Downloads: (external link)
https://unipub.lib.uni-corvinus.hu/2080/ original version (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cvh:coecwp:2015/17

Access Statistics for this paper

More papers in Corvinus Economics Working Papers (CEWP) from Corvinus University of Budapest 1093 Budapest, Fõvám tér 8.. Contact information at EDIRC.
Bibliographic data for series maintained by Adam Hoffmann ().